BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22410063)

  • 1. Bortezomib is effective to treat acute humoral rejection after liver transplantation.
    Lee CF; Eldeen FZ; Chan KM; Wu TH; Soong RS; Wu TJ; Chou HS; Lee WC
    Transplant Proc; 2012 Mar; 44(2):529-31. PubMed ID: 22410063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
    Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
    Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition for antibody-mediated rejection.
    Everly JJ; Walsh RC; Alloway RR; Woodle ES
    Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.
    Leyva S; Marino LA; Alberú J; Morales-Buenrostro LE
    Clin Transpl; 2010; ():369-82. PubMed ID: 21698837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
    Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
    J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
    Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
    Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
    [No Abstract]   [Full Text] [Related]  

  • 8. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for acute humoral rejection in two repeat transplant recipients.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
    Pavlakis M
    Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation.
    Chan KM; Lee CS; Wu TJ; Lee CF; Chen TC; Lee WC
    Transplantation; 2011 Mar; 91(5):e29-30. PubMed ID: 21336085
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
    Island ER; Gonzalez-Pinto IM; Tsai HL; Ruiz P; Tryphonopoulos P; Gonzalez ML; Solano JP; Rossique M; Selvaggi G; Tekin A; Smith LJ; Tzakis AG
    Clin Transpl; 2009; ():465-9. PubMed ID: 20524316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
    Lubetzky M; Auli MJ; Walker J; Leeser D; Kapur S; Hartono C; Dadhania D
    Clin Transpl; 2010; ():437-40. PubMed ID: 21696061
    [No Abstract]   [Full Text] [Related]  

  • 15. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
    Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
    Cooper JE; Wiseman AC; Chan L
    Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
    [No Abstract]   [Full Text] [Related]  

  • 17. Bortezomib rescue in refractory acute humoral rejection--report of a case.
    Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
    Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
    Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E
    Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.